DDS Types
NEXJENNER SERVICE
Brain-delivered DDS Formulation
Lipid Nanoparticle Formulation
LNPs for RNA
Formulation research and development of drug active substances is necessary to increase drug bioavailability, pharmacological effects, and patient compliance.
Nexjenner Co., Ltd. provides services for developing optimized nano drug delivery systems considering
the physical and chemical properties of pharmacologically active substances.
In particular, we have our own DDS formulation platform specialized for brain delivery,
solving difficulties in drug delivery limitations.
DDS Types
Particle Type
Active Ingredient
Nucleic Acid
Protein,
Peptide
Small Molecule
Nonpolar
Carrier Substance
Note
Liposome
O
O
· Phospholipids
· Surfactant
· Triglyceride
· Lonizable Lipids
· Suitable for dissolving
polar substances
· Increased drug stability
· Sustained release
LNPs for RNA
O
· Lonizable Lipids
· Phospholipids
· Cholesterol
· PEG-Lipids
· Specialized in
RNA formulation
using cationic lipids
Lipid Namno-
particle
O
O
O
· Phospholipids
· Cholesterol
· PEG-Lipids
· Poly-lactides (ex: PLGA)
· Polysaccharides
(ex: chitosan, cellulose)
· Oil/Surfactant
· Suitable for
dissolving poorly
soluble substances
· Increased drug stability
· Sustained release
· Size: 20nm~200nm
· Drugs: nucleic acids, hydrophobic drugs, etc.
Lipid Nanoparticle Formulation
LNPs for RNA Formulation
· Size: Nanoparticles of stable size (PDI <0.2)
· Concentration: 0.01-2mg/ml mRNA,
standard 1mg/ml
Formulation
Characteristics
· Increased drug stability and efficacy
· Reduced side effects through sustained release
· High bioavailability due to large surface area
· Improved solubility
· Highly efficient nucleic acid loading
and transformation
· High tissue penetration of the
therapeutic carrier
· Low cytotoxicity and immunogenicity
· Size by DLS (nm)
· Zeta Potential (PDI)
· Size by DLS (nm)
· Zeta Potential (PDI)
· RNA encapsulation by RiboGreen (EE%)